甲方：XXX乙方：XXX20XXCOUNTRACTCOVER專業(yè)合同封面RESUME甲方：XXX乙方：XXX20XXCOUNTRACTCOVER專業(yè)合同封面RESUMEPERSONAL

2025版藥品研發(fā)保密協(xié)議（中英文對照）ConfidentialityAgreementforDrugResearchandDevelopment(ChineseEnglishBilingual)ThisConfidentialityAgreement(“Agreement”)”isenteredintoasof_______________,2025,andbetweenthefollowingparties:PartyA:________________________________________________________________________________________________________________________________________________________________________________________________PartyB:________________________________________________________________________________________________________________________________________________________________________________________________WHEREAS,PartyAisengagedintheresearchanddevelopmentof___________(specifythedrugordrugclass),andPartyBdesirestoreviewcertaininformationconcerningsuchresearchanddevelopment;NOW,THEREFORE,inconsiderationofthemutualcovenantsandpromisescontainedherein,thepartiesagreeasfollows:1.DefinitionofConfidentialInformationForthepurposesofthisAgreement,“ConfidentialInformation”shallmeananyandallnonpublicinformationdisclosedeitherpartytotheother,eitherdirectlyorindirectly,inwriting,orally,orinspectionoftangibleobjects,thatrelatestotheresearch,development,manufacture,use,orsaleof___________(specifythedrugordrugclass).2.ObligationofConfidentialityPartyBagreestoholdtheConfidentialInformationinstrictconfidenceandnottouseitforanypurposeotherthanthereviewandconsiderationoftheresearchanddevelopmentactivitiesofPartyAascontemplatedherein.PartyBshallnotdisclosetheConfidentialInformationtoanythirdpartywithoutthepriorwrittenconsentofPartyA.3.ExclusionsfromConfidentialInformationTheobligationsofconfidentialityunderthisAgreementshallnotapplytoinformationwhich:(a)waspubliclyknownandmadegenerallyavailableinthepublicdomainpriortothetimeofdisclosurePartyAtoPartyB;(c)isalreadyinthepossessionofPartyBatthetimeofdisclosurePartyAasevidencedwrittenrecords;(d)isobtainedPartyBfromathirdpartywithoutabreachofsuchthirdparty'sobligationsofconfidentiality;or(e)isindependentlydevelopedPartyBwithoutuseoforreferencetotheConfidentialInformationofPartyA.4.ReturnofConfidentialInformationUpontheterminationofthisAgreementoruponthewrittenrequestofPartyA,PartyBshallreturnallcopiesofConfidentialInformationtoPartyAorcertify,ifrequested,thedestructionofthesame.5.Term6.TerminationThisAgreementmaybeterminatedeitherpartyuponwrittennoticetotheotherpartyiftheotherparty:(a)breachesanymaterialtermorconditionofthisAgreementandfailstocuresuchbreachwithin___________daysafterreceiptofwrittennoticethereof;or7.GoverningLawThisAgreementshallbegovernedandconstruedinaccordancewiththelawsofthejurisdictioninwhichPartyAisincorporatedorresident.8.EntireAgreementThisAgreementconstitutestheentireagreementbetweenthepartieswithrespecttothesubjectmatterhereofandsupersedesallprioragreements,negotiations,understandings,orrepresentations,whetheroralorwritten,oftheparties.9.ModificationsThisAgreementmaybeamended,modified,orsupplementedonlyawritteninstrumentexecutedbothparties.10.SignaturesINWITNESSWHEREOF,thepartiesheretohaveexecutedthisConfidentialityAgreementasofthedatefirstabovewritten.PartyA:________________________________________________________________________________________________________________________________________________________________________________________________Name:Title:Company:Date:PartyB:________________________________________________________________________________________________________________________________________________________________________________________________Name:Title:Company:Date:附件（Appendix）：（如有需要，可在此處附上詳細(xì)的保密信息清單或其他相關(guān)文件）ConfidentialityAgreementforDrugResearchandDevelopment(ChineseEnglishBilingual)甲方：________________________________________________________________________________________________________________________________________________________________________________________________乙方：________________________________________________________________________________________________________________________________________________________________________________________________鑒于，甲方從事_________（指定藥物或藥物類別）的研究與開發(fā)，乙方希望審查與該研究與開發(fā)相關(guān)的某些信息；現(xiàn)經(jīng)雙方協(xié)商一致，達(dá)成如下協(xié)議：1.保密信息定義本協(xié)議項(xiàng)下，“保密信息”指甲方向乙方直接或間接以書面、口頭或通過檢查有形物體等方式披露的，與_________（指定藥物或藥物類別）的研究、開發(fā)、制造、使用或銷售相關(guān)的任何非公開信息。2.保密義務(wù)乙方同意對保密信息嚴(yán)格保密，并且除本協(xié)議所規(guī)定的目的外，不得將保密信息用于任何其他目的。乙方未經(jīng)甲方事先書面同意，不得向任何第三方披露保密信息。3.保密信息除外(a)在甲方向乙方披露之前，已公開且在公共領(lǐng)域普遍知曉的信息；(b)在甲方向乙方披露之后成為公開且在公共領(lǐng)域普遍知曉的信息，在甲方披露之前該信息已在公共領(lǐng)域；(c)在甲方披露之前，乙方已經(jīng)擁有并能夠證明的書面記錄；(d)乙方從第三方獲得，而第三方未違反其保密義務(wù)的信息；4.保密信息歸還在本協(xié)議終止或甲方書面要求下，乙方應(yīng)將所有保密信息副本歸還甲方或根據(jù)甲方要求證明其已銷毀。5.協(xié)議期限本協(xié)議自首次寫明的日期起生效，有效期為_________年，除非根據(jù)本協(xié)議規(guī)定提前終止。6.終止本協(xié)議可由任何一方在書面通知對方后終止，如果對方：(a)違反本協(xié)議的任何重要條款或條件，并在收到書面通知后的_________天內(nèi)未予以糾正；(b)破產(chǎn)、提交破產(chǎn)申請或成為破產(chǎn)、接管或清算程序的標(biāo)的。7.適用法律本協(xié)議受_________（指定甲方注冊地或居住地所在司法管轄區(qū)）法律的管轄和解釋。8.整體協(xié)議本協(xié)議構(gòu)成雙方就本協(xié)議所涉主題的完整協(xié)議，并取代雙方之前的所有協(xié)議、談判、諒解或表示，無論其是口頭的還是書面的。9.修改本協(xié)議的修改、修改或補(bǔ)充僅可通過雙方簽署的書面文件進(jìn)行。10.簽署本協(xié)議由雙方于上述日期簽署，以資證明。甲方：________________________________________________________________________________________________________________________________________________________________________________________________姓名：職位：公司：日期：乙方：________________________________________________________________________________________________________________________________________________________________________________________________姓名：職位：公司：日期：附件（Appendix）：（如有需要，可在此處附上詳細(xì)的保密信息清單或其他相關(guān)文件）ConfidentialityAgreementforDrugResearchandDevelopment(ChineseEnglishBilingual)甲方：________________________________________________________________________________________________________________________________________________________________________________________________乙方：________________________________________________________________________________________________________________________________________________________________________________________________鑒于，甲方從事_________（指定藥物或藥物類別）的研究與開發(fā)，乙方希望審查與該研究與開發(fā)相關(guān)的某些信息；現(xiàn)經(jīng)雙方協(xié)商一致，達(dá)成如下協(xié)議：1.保密信息定義本協(xié)議項(xiàng)下，“保密信息”指甲方向乙方直接或間接以書面、口頭或通過檢查有形物體等方式披露的，與_________（指定藥物或藥物類別）的研究、開發(fā)、制造、使用或銷售相關(guān)的任何非公開信息。2.保密義務(wù)乙方同意對保密信息嚴(yán)格保密，并且除本協(xié)議所規(guī)定的目的外，不得將保密信息用于任何其他目的。乙方未經(jīng)甲方事先書面同意，不得向任何第三方披露保密信息。3.保密信息除外(a)在甲方向乙方披露之前，已公開且在公共領(lǐng)域普遍知曉的信息；(b)在甲方向乙方披露之后成為公開且在公共領(lǐng)域普遍知曉的信息，在甲方披露之前該信息已在公共領(lǐng)域；(c)在甲方披露之前，乙方已經(jīng)擁有并能夠證明的書面記錄；(d)乙方從第三方獲得，而第三方未違反其保密義務(wù)的信息；4.保密信息歸還在本協(xié)議終止或甲方書面要求下，乙方應(yīng)將所有保密信息副本歸還甲方或根據(jù)甲方要求證明其已銷毀。5.協(xié)議期限本協(xié)議自首次寫明的日期起生效，有效期為_____